Fruquintinib is an oral small molecule tyrosine kinase inhibitor that primarily exerts anti-tumor effects by inhibiting the VEGFR signaling pathway. Its drug interactions mainly involve the CYP3A metabolic enzyme system. The following provides a detailed explanation of the mechanism of action, clinical efficacy, and drug interactions.

1. Mechanism of action and clinical efficacy

Fruquintinib inhibits tumor growth and metastasis by selectively suppressing the tyrosine kinase activity of VEGFR-1/2/3, blocking tumor angiogenesis. Clinical studies have shown that it significantly prolongs the median progression free survival of patients with metastatic colorectal cancer.

2. Drug interactions

(1) CYP3A inhibitors

Strong CYP3A inhibitors (such as itraconazole) may increase the blood concentration of fipronil, and it is recommended to avoid combination therapy. When it is necessary to use it together, the dose of fipronil should be reduced and adverse reactions should be closely monitored.

(2) CYP3A inducer

Levofloxacin and other potent CYP3A inducers may reduce the efficacy of fruquintinib and should be avoided for simultaneous use. If unavoidable, it is necessary to consider increasing the dose of fipronil and monitoring its efficacy.

(3) Anticoagulant drugs

Combined use with anticoagulants such as warfarin may increase the risk of bleeding, and it is necessary to strengthen monitoring of coagulation function. Suggest adjusting the dosage of anticoagulant drugs or switching to low molecular weight heparin.

(4) Proton pump inhibitor

Omeprazole and other drugs may alter the pH value in the stomach, affecting the absorption of furosemide. It is recommended to take or switch to H2 receptor antagonists at intervals of more than 2 hours.

3. Packaging Processing Standards

(1) Original packaging preservation

Tablets should always be kept in their original aluminum foil packaging or medication bottle until taken out before consumption. When packaging with built-in desiccants (such as some bottled formulations), the desiccants should be retained and not discarded.

(2) Sealed and moisture-proof

Immediately cover the bottle cap or seal the edge of the aluminum foil after each medication retrieval. Avoid transferring pills to non original containers such as packaging boxes to prevent moisture damage and failure.